Drug Safety Evaluation Methods in Pregnancy

This white paper reviews the challenges and methodologies associated with evaluating drug safety during pregnancy, particularly for individuals with chronic illnesses requiring ongoing pharmacological treatment. It outlines the critical need for balancing maternal health needs with fetal safety, especially given the lack of data available at the time of drug approval. The paper discusses the role of regulatory guidance in shaping pregnancy exposure studies, emphasizing the importance of real-world data and innovative methodologies to enhance evidence generation. It details various study designs, including drug utilization studies and prospective pregnancy registries, and highlights the evolution of research methodologies due to advancements in data collection technologies. The review also addresses ethical considerations and the necessity for standardized protocols in conducting these studies. Overall, the paper underscores the importance of international collaboration among regulatory agencies to improve drug safety evaluations and support informed therapeutic decisions for pregnant individuals and their infants.